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CLINICAL STUDIES FOR BIOMARKER VALIDATION IN 
OSTEOARTHRITIS 
Michael C Nevitt 
Validated biochemical and imaging biomarkers for osteoarthritis 
(OA) are needed to help speed drug discovery and reduce bot- 
tlenecks in OA treatment evaluation by streamlining and support- 
ing early phase clinical and proof of concept studies. There are 
many potential uses for biomarkers, ranging from understand- 
ing OA etiology and pathogenesis to predicting and monitoring 
the outcome of treatments in individual patients; a diverse spec- 
trum of potential candidates are emerging to meet these needs. 
Candidate biomarkers range from molecular markers that re- 
flect the of synthesis and degradation of joint tissues (e.g. car- 
tilage matrix molecule fragments) or factors that influence these 
processes (e.g. cytokines, proteases), imaging markers that re- 
flect changes in tissue composition (e.g. dGEMRIC) or the out- 
come of pathologic processes on joint tissue morphology (e.g. 
MRI cartilage volume), and susceptibility markers that reflect the 
risk of onset and progression of disease (e.g. genetic markers). 
For biomarkers that have demonstrated acceptable technical per- 
formance (e.g. reliability, precision, dynamic range) the studies 
needed for clinical validation depend, in part, on the purposes of 
the biomarker. Diagnostic markers (disease/no disease) can be 
validated in cross-sectional or case-control studies. Validation of 
predictive or prognostic biomarkers requires longitudinal clinical 
outcome studies. Although such studies allow evaluation of as- 
sociations between baseline levels of, or changes in, biomarkers 
and contemporaneous clinical changes, this type of data is in- 
sufficient o establish the ability of a biomarker to predict, or cor- 
relate with, treatment outcomes. This requires randomized clin- 
ical trials of treatments that demonstrate a clinically meaning- 
ful treatment effect, so that the ability of a baseline measure to 
predict outcomes, and of changes in a marker to track with out- 
comes, can be evaluated. RCTs of disease modifying OA treat- 
ments should ideally include a variety of imaging modalities and 
adequate stored biospecimens to support both biomarker discov- 
ery and validation. In the absence of effective treatments for OA, 
clinical validation of biomarkers will be confined to longitudinal 
observational studies and RCTs that have failed to show a treat- 
ment effect. These should investigate well-defined groups of pa- 
tients with OA, with measurements at multiple time-points of joint 
symptoms and disability, joint imaging, body fluid specimens for 
molecular marker measurement and risk factors. Clinical stud- 
ies of persons with established OA are already yielding useful 
insights into biomarkers for assessing and predicting progression 
of clinical disease. Validation of diagnostic, prognostic and surro- 
gate markers useful in identifying, preventing and treating early or 
preclinical disease requires longitudinal studies in subjects who 
do not have overt clinical OA, but are at risk of developing it. Since 
the most important outcome from a prevention standpoint is the 
onset of clinically significant disease, these studies need to be 
large and long enough, and sufficiently enriched with those at 
risk of developing OA, to yield adequate numbers of new cases 
of clinical disease. 
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THE OSTEOARTHRITIS INITATIVE: WHERE DO WE GO 
FROM HERE? 
GE Lester 
The Osteoarthritis Initiative (OAI) is a longitudinal cohort study 
coordinated by the National Institute on Aging (NIA) and the Na- 
tional Institute on Arthritis and Musculoskeletal and Skin Dis- 
eases (NIAMS) and supported by a public-private partnership 
designed to create a public resource to validate prospective 
biomarkers for diagnosis and monitoring of osteoarthritis. The 
project was initiated in July 2002 and recruitment and enrollment 
of the cohort began in late winter 2004. Currently, there are over 
3500 subjects enrolled in the cohort, which is expected to num- 
ber 4200 by the end of recruitment. One-year follow up measure- 
ments were begun in spring 2005 and to date over 800 have 
been carried out. The cohort contains individuals (60% female) 
with early OA or at high risk of developing OA. The ratio of these 
two groups is 1:2.5. There is a small (<200 subjects) sub-group 
of individuals with no risk of OA or radiologic signs of knee joint 
changes. The clinical data, images, and biospecimens from these 
subjects make up the research resource of the OAI. Within the 
next 3 months, the data from the initial 2500 subjects enrolled in 
the OAI will be available for use by the research community at 
large on the OAI Online website. The purpose of the web site is 
to facilitate data and image sharing, to make it easy for users to 
identify and retrieve data for analysis, and to encourage use of 
the OAI data and images. The clinical data web site will contain 
search and browse variable documentation to allow users to cre- 
ate custom codebooks, to explore data online, and to download 
data as SAS datasets for further analysis. Initial release of images 
will be more limited. There will be pre-made DVDs for distribution 
upon request that contain images from 200 OAI subjects, 100 
from the progression cohort and 100 from the incidence cohort 
selected randomly. Images from all 2000 subjects will be avail- 
able to those users who need them. Access to these images will 
require the submission of a hard drive with 1-2 tarabyte capacity 
for the download. There will be some central image assessment 
done within the OAI. This will include assessment of baseline and 
follow up readings of knee x-rays (KL scores and joint space width 
change), cartilage volume calculations, and readings of baseline 
hand and hip x-rays. As follow up data are accrued, these will be 
added to the data set and linked to the baseline data. Collabo- 
rative and ancillary projects related to data analysis or additions 
to the existing protocol will also be considered by the OAI Steer- 
ing Committee. NIH has plans for future meetings and initiatives 
that will relate to the use and analysis of this research resource. 
These will be announced as funds become available. It is hoped 
that investigators will take advantage of this resource and use 
it as the basis for testing new and novel hypotheses concerning 
osteoarthritis diagnosis, onset, and progression. 
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THE OSTEOARTHRITIS INITATIVE MR PILOT STUDIES 
E Schneider 
The goal of the Osteoarthritis Initiative (OAI) is to create a pub- 
lic database to validate prospective biomarkers, including radio- 
graphic and Magnetic Resonance (MR) images. To ensure the 
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database would not be outdated prior to the end of the study, it 
was necessary to incorporate state-of-the-art MR systems and 
acquisition pulse sequences into the study. Use of 3 Tesla (3T) 
MR systems were selected for the study and several pilot investi- 
gations were undertaken to identify appropriate acquisition proto- 
cols and to cross-validate the quantitative MR measurements to 
those validated irectly. 
The first pilot study, conducted at Ohio State University (OSU), 
had as a goal to help select the optimal acquisition, including 
planes, parameters and pulse sequences for the OAI. MR images 
were obtained in thirteen knees at 3T using sixteen different ac- 
quisitions. These initial MR acquisitions were selected by the OAI 
Imaging Committee after several rounds of protocol optimization 
had been performed. 
Nine 3D series, including two multi-planar eformats (MPRs), 
were evaluated for suitability for cartilage segmentation by five 
persons from cartilage segmentation teams. Nine 2D series, in- 
cluding two multi-slice multi-echo (MSME) T2 map acquisitions, 
were evaluated by six musculoskeletal radiologists for suitabil- 
ity to assess joint structural integrity as well as for discrimi- 
nation of cartilage defects, bone marrow edema-like (BME) le- 
sions and bone cysts. Evaluation criteria included cartilage con- 
trast/structure discrimination relative to surrounding tissues, pres- 
ence/extent of image artifacts, anatomic coverage, fat suppres- 
sion uniformity, and signal uniformity. 
A second pilot study for the OAI, conducted at OSU and Memorial 
Hospital of Rhode Island (MHRI), acquired test-retest MR images 
in the knees of 19 subjects with no to moderate degrees of clin- 
ical OA. Two studies with double oblique coronal 3D FLASH se- 
quences with water excitation (WE) and 1.5mm slice thickness 
were acquired at 3T. In addition, two studies with sagittal 3D 
DESS WE sequences with 0.7mm slice thickness were also ac- 
quired. From the sagittal 3D DESS acquisitions, double oblique 
coronal multi-planar reformats (MPR) were performed at 1.5mm 
slice thickness. 
Knee cartilage volume, surface area, thickness and subcortical 
bone surface area were quantified by four analysis teams in an 
unpaired manner from the 114 image series. Subject identifica- 
tion, image pairs and series were blinded. Regions of interest 
and segmentation rules were determined by concensus of all four 
teams prior to distribution of the blinded images. 
The MR imaging protocol which resulted from the initial pilot study 
will be presented. In addition, a summary of the range of individ- 
ual team results as well as the meta-analysis of the segmentation 
results from the second pilot study will be presented along with a 
description of the subject cohort. A synopsis of the ongoing MR 
pilot studies will also be presented. 
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OA BIOMARKERS: THE CLINICAL TRIAL PERSPECTIVE. 
RADIOGRAPHY 
Marie-Pierre Hellio Le Graverand 
Conventional radiography is the simplest and least expensive 
method for imaging joints in osteoarthritis (OA). Radiographs 
clearly visualize bony features including marginal osteophytes, 
subchondral sclerosis and subchondral cysts that are associated 
with OA but provide only an estimate of cartilage thickness by 
the interbone distance or joint space width (JSW). Radiography 
is used in clinical practice to establish the diagnosis and to moni- 
tor the progression of OA. Various radiographic definitions of OA 
have been proposed. The radiographic definition of OA relies pri- 
marily on the evaluation of both osteophytes and joint space nar- 
rowing (JSN), while the assessment of OA severity relies largely 
on JSN and subchondral bone lesions. Progression of JSN is the 
most commonly used criterion for the assessment of OA progres- 
sion and the complete loss of JSW characterized by bone on 
bone contact is a factor considered in the decision for joint re- 
placement. The growing number of publications on radiographic 
assessment of OA over the recent past years highlights a re- 
newed interest in the assessment of disease progression driven 
in particular by randomized controlled clinical trials (RCTs) for 
Disease Modifying OA Drugs (DMOADs). In the past, studies 
generally used standard plain radiographs (i.e., anteroposterior 
(AP) view of the pelvis for the hip and standing AP view of the 
femorotibial joint for the knee). In recent years, the precision and 
sensitivity of standard plain radiographs for detecting early OA 
and measuring disease progression has been questioned. In ad- 
dition, the demonstration of chondroprotection i DMOAD RCTs 
has demonstrated to be a significant challenge using radiogra- 
phy. This presentation will review the limitations of conventional 
radiography and the progress that has been made in the recent 
years. 
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MAGNETIC RESONANCE IMAGING: DISEASE 
MODIFYING OSTEOARTHRITIS DRUG CLINICAL TRIAL 
PERSPECTIVE 
JL Evelhoch 
More sensitive biomarkers of cartilage degradation are needed to 
facilitate development of disease modifying osteoarthritis drugs 
(DMOAD). Over the past decade, magnetic resonance imaging 
(MRI) techniques, with 3-dimensional imaging capability and high 
soft tissue contrast, have been developed for quantifying cartilage 
morphology throughout the knee. Quantitative cartilage morphol- 
ogy measurements by MRI correlate strongly with independent 
measurements made in specimens from cadavers and/or total 
knee arthroplasty. Longitudinal quantitative MRI studies of OA 
patients indicate that total cartilage volume decreases 4-6% per 
year, with twice that regionally. The variability (test-retest) of total 
cartilage volume in single center studies is 3-4% at 1.5 T(esla) 
and is reduced to 2-3% at 3 T. Thus, multi-center studies should 
be able to detect treatment effects on cartilage degradation in 6- 
12 months with a hundred subjects per arm. Due to the face va- 
lidity of MRI cartilage measurements, there is great interest within 
the drug development industry and regulatory bodies to evaluate 
the potential of quantitative MRI measurements of cartilage mor- 
phology as a surrogate endpoint. 
In addition to these morphometric measurements, several MRI 
methods have been developed to assess cartilage composition, 
including T2, TII~, dGEMRIC and sodium imaging. The T2 and 
T11~ methods rely on changes in these MR properties due to al- 
terations in the biophysical environment of water resulting from 
changes in the cartilage composition. The dGEMRIC (delayed 
Gadolinium Enhanced MRI of Cartilage) and sodium imaging 
methods take advantage of the negative charge of glycosamino- 
glycan (GAG, a principal component of aggrecan), which de- 
creases the amount of Gd(DTPA)2- (i.e., most widely used MRI 
contrast agents) and increases the amount of sodium that pen- 
etrates the cartilage. Since dGEMRIC uses the higher sensitiv- 
ity (and resulting spatial resolution) of proton MRI to image the 
contrast agent distribution, its use to non-invasively assess the 
GAG distribution is of particular interest. Aggrecan is lost in hu- 
man cartilage regions with no detectable collagen loss and de- 
grades before collagen during stimulated cartilage breakdown, 
so it may protect cartilage collagen from degradation. Thus, as 
suggested by the observation that in patients with hip dysplasia, 
the dGEMRIC index, but not JSW, correlates with pain and the 
severity of the dysplasia, dGEMRIC measurement of aggrecan 
depletion could provide an early indicator of OA progression or 
drug effect. Further evaluation of the performance of dGEMRIC 
and the other MR-based methods to assess cartilage composi- 
tion in the context of clinical trials is needed to determine their 
